Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

NCT00538109 is registered in ClinicalTrials.gov with King Faisal Specialist Hospital & Research Center as lead sponsor.

NCT NCT00538109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00538109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
Lead sponsor
King Faisal Specialist Hospital & Research Center
Phase
Not applicable
Overall status
Completed
Start date
October 31, 2007
Completion date
October 31, 2013
Enrollment
8 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, chronic